BACE1 and Alzheimer disease: An expanding array of research supports the efficacy of both genetic knockdown of BACE1 and the use of BACE1 inhibitors in reducing Aβ levels, leading to improvements in synaptic and cognitive dysfunction in AD model mice (Ohno et al., 2004; McConlogue et al., 2007; Neumann et al., 2015).